Inhaler option makes insulin more acceptable
|
Tweet
|
|
Giving patients who have type 2 diabetes, or adult-onset diabetes, the option of using an insulin inhaler may help them comply with insulin treatment recommendations, new findings suggest.
The study was funded by Pfizer and Aventis, which are developing inhaled insulin under the trade name Exubera. Experts have predicted the drug may be on the market later this year or sometime in 2006.
As reported in the medical journal Diabetes Care, Dr. Nick Freemantle, from the University of Birmingham in the UK, and colleagues assessed the rate of insulin usage among 779 diabetics who received educational information on currently licensed treatments with or without information on inhaled insulin.
All of the subjects in the study had type 2 diabetes for at least 3 months and had inadequate control of their sugar levels despite being on therapy, according to the report.
After receiving the information materials, patients were surveyed about their treatment preferences.
Forty-three percent of patients given information about licensed drug treatments and inhaled insulin preferred a treatment that included insulin. By contrast, just 16 percent of patients who were told only about licensed treatment (including insulin injections) selected some form of insulin therapy.
Although all patients had less than optimal control of their sugar levels, those in the inhaled insulin group were more likely to consider changing their current treatment regimen than were those who were told only about licensed therapies.
In both groups, as the number of anti-diabetes pills currently taken rose, so did the likelihood of selecting an insulin therapy. However, this trend was more pronounced in the group given information on inhaled insulin than in the comparison group.
Having inhaled insulin as a treatment option may help “overcome patient aversion to insulin therapy, and its availability may thus enable patients to act in accordance with the recommendations of their physicians,” the authors note.
SOURCE: Diabetes Care, February 2005.
Revision date: July 6, 2011
Last revised: by Sebastian Scheller, MD, ScD
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Best time for a coffee break? There’s an app for that
- Full Story - - »»»
Cellphone Use Linked to Selfish Behavior in UMD Study
- Full Story - - »»»
Optimism about heart risks may be a good thing
- Full Story - - »»»
New guidelines developed for improved DVT diagnosis
- Full Story - - »»»
Teen pregnancy, abortion rates at record low, study says
- Full Story - - »»»
Think you can’t get pregnant? Try again, study says
- Full Story - - »»»

